Peptide cycles per year: no number exists

The question of how many peptide cycles to run in a year has no published answer, and that is not because the answer is buried in a paper nobody reads. It is because the clinical literature on Semax, Selank and the blends sold as Klow never studied repeated annual courses at all. Cycle lengths circulate freely, since a handful of trials stated how long they dosed people for. Cycle counts do not circulate, because nobody measured them.

The honest version of the answer is that repeat-exposure evidence is the specific thing missing here, and it is missing for every compound in the question.

Cycling came from bodybuilding, not from a clinic

Cycling as a practice grew out of anabolic steroid use. The US National Institute on Drug Abuse describes it as taking multiple doses over a set period, stopping for a period, then starting again, alongside the related habits it calls stacking, pyramiding and plateauing^[1]. NIDA is blunt about the evidence behind those regimens, stating that the effects of pyramiding, cycling and plateauing have not been substantiated scientifically^[1].

That convention travelled into peptide forums intact, and it arrived without the pharmacology that produced it. A steroid cycle is built around suppression of the body's own hormone output and the recovery window that follows. Neither BPC-157 nor Semax acts on that axis, so the reasoning behind the schedule does not carry over, even loosely.

What the Semax trials administered

The Russian clinical record is where the Semax cycle lengths come from. Gusev and colleagues followed 110 stroke patients, 43 men and 67 women with a mean age of 58.0 plus or minus 9.7 years, and the trial administered what the authors call two courses of 10 days at 6,000 micrograms a day, separated by a 20-day interval, with observation running about 5 months^[2]. A 2007 study in 27 patients with motor neuron disease used 12 mg a day intranasally, again as two 10-day courses with a two-week break^[3]. An earlier acute-stroke study dosed 30 patients for 5 and 10 days, at 12 mg or 18 mg depending on how severe the stroke was^[4].

Read those together and the shape is clear. Each was a single treatment episode aimed at one clinical problem, delivered intranasally under supervision, and then it stopped. No trial in this set repeated its protocol a year later, and none was designed to. Our Semax page and our walk-through of what the Semax trials actually dosed go through the numbers in more detail.

The Selank record is smaller still

Selank has no hub page on this site because its published human record fits in a paragraph. Zozulia and colleagues compared Selank in 30 patients against the benzodiazepine medazepam in 32, in generalised anxiety disorder and neurasthenia^[5]. A 2014 comparison against phenazepam covered 60 patients with phobic-anxiety and somatoform disorders^[6]. Both were single treatment episodes in a psychiatric population, and neither reported anything about running the course again.

A 2020 forensic paper in Drug Testing and Analysis, written after Semax and Selank turned up in seized pharmaceutical preparations and in products sold online, put the position plainly: these peptides have not completed any clinical trials^[7]. That is the evidence base the cycling question is being asked about.

Klow is a trade name, not a medicine

Klow is a label used by research-chemical sellers for a multi-peptide blend, and we could not verify what belongs in it from any citable source. That failure is the finding. A DailyMed search returns no labelled product under the name^[8], and no pharmacopoeial monograph fixes the contents or the strength. Where there is no approved product there is no approved schedule, so there is nothing defined to repeat and nothing to count. We looked at the wider problem with these blends in our piece on stacking one with retatrutide.

The individual peptides usually associated with repair blends sit in the same place. The US Department of Defense Operation Supplement Safety programme calls BPC-157 an unapproved drug that cannot legally be prescribed or sold over the counter, and says there is little to no reliable scientific evidence for its safety or effectiveness in humans^[9]. TB-500 has no human dose-finding trial to build a schedule around either. Country status for both sits on our United States and United Kingdom pages.

The same absence shows up on the two national databases that would settle it. Semax and Selank each return zero results in DailyMed, the US archive of approved label text^[8], and zero results in the UK electronic medicines compendium^[10]. The regulatory position on Semax is covered on its hub page, and Germany and the Netherlands have their own pages.

What we do not know

Repeat-exposure safety is the gap, and it is a wide one. Nobody has published what happens to a healthy person who runs the same peptide course three or four times across a year. There is no measurement of whether the effect holds, fades or reverses on a second or third exposure. Antibody formation, receptor changes and cumulative organ effects over that horizon are unmeasured too. A 2026 review of therapeutic peptides in gerontology, which covers Semax among the non-approved compounds, names dosing regimens and long-term safety data as open gaps across this whole category^[11].

Product identity adds a second layer. The seized-preparation work exists precisely because material sold as Semax or Selank is not always what the label claims^[7], and a blend spreads that uncertainty across every component in the vial. Repeating an exposure you cannot characterise is a different risk from repeating a known one, which is part of why BPC-157 and TB-500 questions keep coming back to supply before they get to schedules.

A better question to bring to a clinician

If you are weighing repeated use of any of these, the useful conversation is with a doctor who knows your history and your other medications. A clinician cannot cite a cycle count either, because none exists. What a clinician can do is tell you whether the condition you are treating has an approved treatment with real safety data behind it.

This article is educational and journalistic and is not medical advice. It does not say how much of anything to use, or how often, because the evidence needed to answer that has not been produced.